Hypertension Clinical Trial
Official title:
A Prospective, Multicentre, Randomized, Open Label, Evaluator-Blind, Phase IV Study to Evaluate the Effect on Improvement of Left Ventricular Hypertrophy by the Control of Blood Pressure in Hypertension Patients With Aortic Valve Disease
Verified date | September 2022 |
Source | Hanmi Pharmaceutical Company Limited |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on improvement of left ventricular hypertrophy and its safety
Status | Completed |
Enrollment | 128 |
Est. completion date | July 25, 2022 |
Est. primary completion date | July 25, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Male or female aged = 19 years and < 80 years 2. Diagnosis of mild-moderate AS or mild-moderate AR 3. Applicable to 2.0~3.9 m/s of aortic jet velocity for mild-moderate AS or to 0.2~0.6 cm of Vena contracta for mild-moderate AR 4. Diagnosis of hypertension (SBP > 130 mmHg if being treated or SBP > 140 mmHg if being untreated) 5. For females of childbearing potential; negative pregnancy test results during the screening period and prior to administration of the investigational product, and agreement on use of medically allowable contraceptive measures (condom, oral contraceptive pills, injectable or implantable contraceptives, intrauterine devices, birth control patches, etc.) during the study period 6. Voluntary written consent to taking part in the clinical study and willingness to comply with requirements of the study Exclusion Criteria: 1. History of a cardiac valve replacement surgery (replacement surgery of mitral valve, aortic valve or tricuspid valve) 2. Accompanied by severe mitral regurgitation 3. Admitted to needing a surgery by the current treatment guidelines 4. Accompanied by symptoms such as angina pectoris, exertional dyspnea, syncope, etc. 5. < 50% of left ventricular ejection fraction 6. History of hypersensitivity reaction to active ingredients of the investigational product (Amlodipine, Losartan and Chlorthalidone), dihydropyridine derivatives, thiazide drugs and other sulfonamide derivatives or their compositions 7. Pregnant or breastfeeding 8. Symptomatic orthostatic hypotension 9. Severe liver failure or renal failure (< 30 mL/min of creatinine clearance) 10. Hereditary angioedema or history of angioedema at treatment with ACE inhibitors or angiotensin II receptor blockers 11. Primary hyperaldosteronism 12. Genetic problems such as galactose intolerance, Lapp Lapp lactase deficiency or glucose-galactose malabsorption 13. Anuria 14. Refractory hypokalemia 15. Hyponatremia or hypercalcemia 16. Symptomatic hyperuricemia (history of gout or uric acid lithiasis) 17. Untreated Addison's disease 18. Appropriately uncontrolled diabetes 19. Congenital or incurable hypertension 20. Diagnosis of severe cerebrovascular disorders (stroke, cerebral infarction, cerebral hemorrhage, etc.) within six months prior to the date of ICF obtainment 21. Wasting disease, autoimmune disease or connective tissue disease 22. Diagnosis of malignant tumor within five years prior to the date of ICF obtainment 23. Administration of another investigational product within four weeks prior to the date of ICF obtainment 24. For a patient who is taking anticoagulants and thrombolytic agents; considered difficult to keep a stable dosage/regimen by the investigator. 25. Considered unsuitable to be a subject by the investigator |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | 10 Institutions Including Asan Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
Hanmi Pharmaceutical Company Limited |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Occurrence and frequency of adverse events | Occurrence and frequency of adverse events | 6 months, 12 months, 18 months, 24 months | |
Primary | To evaluate changes from baseline in Left Ventricular Mass at 24M | To evaluate changes from baseline in Left Ventricular Mass at 24M | 24 months | |
Secondary | Changes from baseline in Left Ventricular global longitudinal strain at 24M | Changes from baseline in Left Ventricular global longitudinal strain at 24M | 24 months | |
Secondary | Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M | Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M | 24 months | |
Secondary | Changes from baseline in Left Ventricular volumes at 24M | Changes from baseline in Left Ventricular volumes at 24M | 24 months | |
Secondary | Rate of disease progression | In case of Aortic Stenosis, to evaluate changes from baseline in Aortic Valve Area, tricuspid regurgitation velocity, Mean Pressure Gradient and Valvulo-arterial impedance at 24M
In case of Aortic Regurgitation, to evaluate changes from baseline in Vena contracta at 24M |
24 months | |
Secondary | To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M | To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M | 6 months, 12 months, 18 months, 24 months | |
Secondary | Cumulative incidence rate for each visit time point | Cumulative incidence rate for each visit time point
- Death, Cardiovascular death, Heart Failure, Myocardial Infarction, Hospitalization, Aortic Valve Replacement |
6 months, 12 months, 18 months, 24 months | |
Secondary | Changes from baseline in stroke volume index at 24M | Changes from baseline in stroke volume index at 24M | 24 months | |
Secondary | Changes from baseline in Left Ventricular ejection fraction at 24M | Changes from baseline in Left Ventricular ejection fraction at 24M | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04591808 -
Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
|
Phase 3 | |
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT05433233 -
Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension
|
N/A | |
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Completed |
NCT03093532 -
A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT05529147 -
The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
|
||
Recruiting |
NCT05976230 -
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
|
||
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Completed |
NCT06008015 -
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT05387174 -
Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Recruiting |
NCT05121337 -
Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension
|
N/A | |
Withdrawn |
NCT04922424 -
Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men
|
Phase 1 | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Not yet recruiting |
NCT05038774 -
Educational Intervention for Hypertension Management
|
N/A | |
Completed |
NCT05087290 -
LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
|
||
Completed |
NCT05621694 -
Exploring Oxytocin Response to Meditative Movement
|
N/A | |
Completed |
NCT05688917 -
Green Coffee Effect on Metabolic Syndrome
|
N/A | |
Recruiting |
NCT05575453 -
OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure
|
N/A |